MiR-608, pre-miR-124-1 and pre-miR26a-1 polymorphisms modify susceptibility and recurrence-free survival in surgically resected CRC individuals
Metrics: PDF 1650 views | HTML 2318 views | ?
Hou-Qun Ying1,4,*, Hong-Xin Peng2,4,*, Bang-Shun He4,*, Yu-Qin Pan4, Feng Wang3,4, Hui-Ling Sun4, Xian Liu4, Jie Chen4, Kang Lin4, Shu-Kui Wang4
1Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
2Medical School of Southeast University, Nanjing 210009, Jiangsu, China
3Department of Clinical Laboratory, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China
4Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China
*These authors have contributed equally to this work
Shu-Kui Wang, email: [email protected]
Keywords: miRNA, colorectal cancer, polymorphism, clinical outcome
Received: November 03, 2015 Accepted: September 25, 2016 Published: October 04, 2016
Genetic variation within microRNA (miRNA) may result in its abnormal folding or aberrant expression, contributing to colorectal turmorigenesis and metastasis. However, the association of six polymorphisms (miR-608 rs4919510, miR-499a rs3746444, miR-146a rs2910164, pre-miR-143 rs41291957, pre-miR-124-1 rs531564 and pre-miR-26a-1 rs7372209) with colorectal cancer (CRC) risk, therapeutic response and survival remains unclear. A retrospective study was carried out to investigate the association in 1358 0-III stage resected CRC patients and 1079 healthy controls using Sequenom’s MassARRAY platform. The results showed that rs4919510 was significantly associated with a decreased susceptibility to CRC in co-dominant, allele and recessive genetic models, and the protective role of rs4919510 allele G and genotype GG was more pronounced among stage 0-II cases; significant association between rs531564 and poor RFS was observed in cases undergoing adjuvant chemo-radiotherapy in co-dominant, allele and dominant models; moreover, there was a positive association between rs7372209 and recurrence-free survival in stage II cases in co-dominant and over-dominant models; additionally, a cumulative effect of rs531564 and rs7372209 at-risk genotypes with hazard ratio at 1.30 and 1.95 for one and two at-risk genotypes was examined in stage II cases, respectively. Our findings indicated that rs4919510 allele G and genotype GG were protective factors for 0-II stage CRC, rs7372209 and rs531564 could decrease RFS in II stage individuals and resected CRC patients receiving adjuvant chemo-radiology.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.